ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,092Medicare Part D Prescriptions Filled, Including Refills

Rank: 84 out of 337

$450K Total Retail Price of All Prescriptions

Rank: 90 out of 337

356 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
23% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Rhode Island
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 356 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

10% of this provider’s 356 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

1% of this provider’s 7,529 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$50 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Rhode Island
AMLODIPINE BESYLATE 483 447 1 3
SIMVASTATIN 388 280 2 1
HYDROCHLOROTHIAZIDE 334 297 3 9
LISINOPRIL 323 254 4 2
LEVOTHYROXINE SODIUM 274 214 5 5
LISINOPRIL-HYDROCHLOROTHIAZIDE 235 192 6 31
OMEPRAZOLE 235 178 6 4
PRAVASTATIN SODIUM 234 200 8 14
METOPROLOL TARTRATE 196 184 9 6
ATENOLOL 159 134 10 10
ATORVASTATIN CALCIUM 149 148 11 7
CARVEDILOL 147 135 12 73
ZOLPIDEM TARTRATE 142 122 13 23
SERTRALINE HCL 140 127 14 18
METFORMIN HCL 137 87 15 12
WARFARIN SODIUM 133 120 16 11
HYDROCODONE-ACETAMINOPHEN 132 118 S3 17 13
FUROSEMIDE 129 116 18 8
LOSARTAN-HYDROCHLOROTHIAZIDE 129 125 18 60
ALLOPURINOL 122 80 20 28
LOSARTAN POTASSIUM 111 110 21 15
DIGOXIN 105 105 22 58
METOPROLOL SUCCINATE 105 95 22 21
AMLODIPINE BESYLATE-BENAZEPRIL 96 96 24 97
GLIMEPIRIDE 95 84 25 55
CRESTOR 92 58 26 29
GABAPENTIN 82 70 27 20
CITALOPRAM HBR 82 82 27 17
PREDNISONE 77 68 29 40
PANTOPRAZOLE SODIUM 74 53 30 36
NEXIUM 70 36 31 56
LACTULOSE 68 20 32 105
FENOFIBRATE 67 44 33 48
TAMSULOSIN HCL 65 65 34 25
CLOPIDOGREL 64 63 35 42
FLUOXETINE HCL 62 21 36 57
CLONIDINE HCL 62 49 36 135
COLCRYS 62 49 36 128
FLUTICASONE PROPIONATE 60 46 39 34
SPIRIVA 60 60 39 43
LIPITOR 58 58 41 33
INSULIN SYRINGE 57 48 42 127
PROAIR HFA 55 49 43 38
DICLOFENAC SODIUM 54 41 44 211
DIOVAN HCT 53 53 45 88
PLAVIX 51 47 46 74
TRAZODONE HCL 50 50 47 16
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 9, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.